Document is current
Any future updates will be listed below
-
Authors
Chan, Wan Ching https://orcid.org/0000-0002-0758-0066
Kwok, Man Long
Qu, Xinyan
Abdelkarim, Hazem
Le, Jonathan
Yang, Deying
Banerjee, Avik https://orcid.org/0000-0002-0668-5480
Zhao, Shuangping
Class, Jacob
Gonzalez, Marlen
Hailemeskel, Harry
Singh, Raman Ghotra
Gallardo-Macias, Ricardo https://orcid.org/0009-0008-1486-8261
Gurvich, Vadim J. https://orcid.org/0000-0002-5420-1639
Maienschein-Cline, Mark
Lindeblad, Matthew
Kabirov, Kasim
Lyubimov, Alexander V.
Belvitch, Patrick
Richner, Justin https://orcid.org/0000-0002-5344-118X
Gaponenko, Vadim
Komarova, Yulia A.
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0639)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HHSN268201700007C, R01HL045638)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002003)
- License Information
-
More Information
Article History
Received: 25 April 2025
Revised: 22 September 2025
Accepted: 14 October 2025
First Online: 18 November 2025
Competing interests
: Y.A.K. and V.G. have submitted a provisional patent application on the VT-109 composition matter and method of treatment for A.R.D.S. The authors declare that they have no other competing interests.
